The World Health Organization’s decision to deploy Ervebo highlights the desperate need for any clinical tool that might lower the high mortality rate of the Bundibugyo virus. Since the declaration of the emergency in May 2026, the Democratic Republic of the Congo has faced a relentless escalation
The cost of delivering vaccines in remote mountainous regions far exceeds urban delivery, suggesting that truly equitable funding must account for geographic and logistical challenges. This realization marks a shift in how global health experts perceive the efficacy of international aid.
Medical professionals are documenting surprising improvements in arthritis symptoms and joint mobility that appear entirely independent of a patient's actual weight loss. This unexpected therapeutic success has shifted the clinical narrative surrounding glucagon-like peptide-1 receptor agonists
The era of treating computational discovery as a validated shortcut to clinical trials is ending as prospective evidence reveals significant inconsistencies in performance. The biopharmaceutical industry reached a critical juncture in early 2026 when the first large-scale, blinded evaluation of
Public health has moved from a technocratic discipline into a politically charged arena where practitioners must navigate a deeply polarized social landscape. The Boston University School of Public Health (BUSPH) has spent the last half-century evolving from a localized initiative into a global
The immunotherapy revolution is fundamentally reshaping the treatment landscape for liver cancer by displacing older, single-agent systemic therapies with advanced combinations. As the global healthcare sector enters a period of unprecedented investment, the financial trajectory for liver cancer
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59
